AXGN News Alert Axogen Inc. (AXGN) 3.07 12/17/2014 03:34:10

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Axogen Inc. (AXGN) 3.07 $AXGN

Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
DXLG: 5.00 (+0.02), GPN: 77.27 (-1.47), AXGN: 3.07 (-0.09), ARQL: 1.16 (unch), ELNK: 3.97 (-0.17)

Will AxoGen (AXGN) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 8:05AM CST
Will AxoGen (AXGN) Continue to Surge Higher?
AXGN: 3.07 (-0.09)

AxoGen, Inc. CEO Karen Zaderej to Be Interviewed on Clear Channel - iHeart Business Talk Radio's "The Trader's Network" on December 2
GlobeNewswire - Tue Dec 02, 6:17AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a high-growth medical technology company focused on the peripheral nerve repair market, announced today that Chief Executive Officer (CEO) Karen Zaderej will be interviewed live by host Michael Yorba on Clear Channel - iHeart Business Talk Radio's "The Trader's Network" Show. In this exclusive interview, Ms. Zaderej will discuss AxoGen's unique and innovative portfolio of peripheral nerve repair solutions that offer alternatives to the more than 900,000 patients each year who require surgical repair of an injured peripheral nerve. She will also discuss the Company's strong year-on-year growth and its strategy for becoming the market leader of the $1.6 billion peripheral nerve repair market in the US.
AXGN: 3.07 (-0.09)

AxoGen, Inc. CEO Karen Zaderej to Be Interviewed on Clear Channel -- iHeart Business Talk Radio's "The Trader's Network" on December 2nd, 2014
Marketwired - Tue Dec 02, 6:15AM CST
AxoGen, Inc. (NASDAQ: AXGN), a high-growth medical technology company focused on the peripheral nerve repair market, announced today that Chief Executive Officer (CEO) Karen Zaderej will be interviewed live by host Michael Yorba on Clear Channel -- iHeart Business Talk Radio's "The Trader's Network" Show. In this exclusive interview, Ms. Zaderej will discuss AxoGen's unique and innovative portfolio of peripheral nerve repair solutions that offer alternatives to the more than 900,000 patients each year who require surgical repair of an injured peripheral nerve. She will also discuss the Company's strong year-on-year growth and its strategy for becoming the market leader of the $1.6 billion peripheral nerve repair market in the US. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel's nationally syndicated iHeart Radio stream.
AXGN: 3.07 (-0.09)

AxoGen (AXGN) Looks Good: Stock Adds 5.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 8:46AM CST
AxoGen (AXGN) was a big mover last session, with shares rising nearly 6% on the day.
IPXL: 29.09 (-1.55), AXGN: 3.07 (-0.09), AKRX: 37.55 (-2.17), MYL: 53.56 (-0.96)

PDL BioPharma Announces Successful Conclusion of Revenue Interest Agreement with AxoGen
PR Newswire - Fri Nov 14, 6:00AM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company has received $30.3 million, in addition to previously received revenue interest payments, to conclude PDL's revenue interest agreement with AxoGen, Inc. (NASDAQ: AXGN). In October 2012, PDL entered into a structured financing transaction in which PDL provided AxoGen with an aggregate of $20.8 million in exchange for royalties on certain AxoGen revenues. AxoGen is a regenerative medicine company dedicated to advancing the science and commercialization of surgical solutions for peripheral nerve repair.
AXGN: 3.07 (-0.09), PDLI: 7.32 (-0.07)

AxoGen's (AXGN) CEO Karen Zaderej on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 7:19PM CST

AXGN: 3.07 (-0.09)

AxoGen beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 5:41PM CST

AXGN: 3.07 (-0.09)

AxoGen, Inc. Signs Agreement with Oberland Capital
GlobeNewswire - Thu Nov 13, 3:09PM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, has entered into a $28.55 million financing agreement with Three Peaks Capital S.a.r.l., an indirect wholly-owned subsidiary of Oberland Capital Healthcare Master Fund LP (collectively "Oberland" . The financing from Oberland, along with $1.75 million in capital from the Company, enables AxoGen to retire the Company's royalty agreement with PDL BioPharma, Inc. and substantially reduces AxoGen's future annual debt payments.
AXGN: 3.07 (-0.09), PDLI: 7.32 (-0.07)

AxoGen, Inc. Reports 58% Third Quarter Revenue Growth
GlobeNewswire - Thu Nov 13, 3:09PM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, grew revenue during the third quarter to $4.67 million, up 58% as compared to the year ago third quarter revenue of $2.96 million. The growth was driven by the successful execution of management's growth strategies, which are focused on increasing sales to existing customers and the addition of targeted new customers.
AXGN: 3.07 (-0.09)

AxoGen, Inc. to Report Third Quarter Financial Results on November 13, 2014
GlobeNewswire - Thu Nov 06, 6:09AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, will report results for the third quarter ended September 30, 2014 on Thursday, November 13, 2014 after the market closes.
AXGN: 3.07 (-0.09)

AxoGen (AXGN) Shows Strength: Stock Up 15.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 8:39AM CDT
AxoGen, Inc. (AXGN) was a big mover last session, as its shares rose over 15% on the day.
MNK: 91.05 (-1.12), ACT: 256.52 (-6.48), AXGN: 3.07 (-0.09), MYL: 53.56 (-0.96)

AxoGen, Inc. Announces Presentation of Clinical Data for Avance(R) Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting
GlobeNewswire - Tue Sep 30, 6:05AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, announced the presentation of clinical data for Avance(R) Nerve Graft during the American Society for Surgery of the Hand (ASSH) 2014 Annual Meeting which took place last week in Boston.
AXGN: 3.07 (-0.09)

Surgeon Attendance at AxoGen's Education Events Exceeds Expectations
GlobeNewswire - Thu Sep 25, 6:02AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, reported attendance at two recent surgeon education events exceeded management's expectations and registration at two upcoming professional education seminars is near capacity. The event at the American Society for Surgery of the Hand (ASSH) in Boston, held this past week, drew surgeons interested in nerve repair in the upper extremity from the US and multiple other countries. Surgeons focused on repair of the trigeminal nerve in the lower jaw attended an event at the American Association of Oral and Maxillofacial Surgeons (AAOMS) annual meeting in Hawaii.
AXGN: 3.07 (-0.09)

AxoGen, Inc. to Host Surgeon Education Event at American Society for Surgery of the Hand 2014 Annual Meeting
GlobeNewswire - Tue Sep 16, 6:13AM CDT
via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), a leading medical technology company focused on the peripheral nerve repair market, announced that it will sponsor an educational forum at the American Society for Surgery of the Hand (ASSH) 2014 Annual Meeting, taking place September 18-20 at the John B. Hynes Convention Center in Boston, MA.
AXGN: 3.07 (-0.09)

AxoGen, Inc. to Host Surgeon Panel on Nerve Repair at American Association of Oral and Maxillofacial Surgeons Annual Meeting 2014
GlobeNewswire - Tue Sep 09, 6:04AM CDT
via PRWEB - A xoGen, Inc. (Nasdaq:AXGN), a leader in the science and commercialization of surgical solutions for peripheral nerve repair, today announced that it will sponsor a panel discussion at the 96th Annual Meeting of the American Association of Oral and Maxillofacial Surgeons (AAOMS), taking place this week in Honolulu, HI. The Company will also demonstrate its full portfolio of nerve repair products during the clinical conference at Booth 644.
AXGN: 3.07 (-0.09)

AxoGen, Inc. Announces Changes to Board of Directors
GlobeNewswire - Mon Aug 25, 3:08PM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, reported today that John McLaughlin, President and Chief Executive Officer of PDL BioPharma, Inc. has resigned from AxoGen's Board of Directors.
AXGN: 3.07 (-0.09), PDLI: 7.32 (-0.07)

AxoGen, Inc. to Present at the Wedbush 2014 Life Sciences Management Access Conference
GlobeNewswire - Tue Aug 05, 6:08AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the $1.6 billion US peripheral nerve repair market, is scheduled to present at the Wedbush 2014 Life Sciences Management Access Conference on Tuesday, August 12, 2014 at 10:55am (ET) at Le Parker Meridien Hotel in New York City.
AXGN: 3.07 (-0.09)

AxoGen, Inc. Reports 47% Second Quarter Revenue Growth
GlobeNewswire - Mon Aug 04, 3:07PM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, announced record quarterly revenue of $4.21 million for the second quarter ended June 30, 2014, representing growth of 47% as compared to $2.86 million for the second quarter of 2013. The increase in revenue was driven by increased unit sales to existing customers and the addition of new customers.
AXGN: 3.07 (-0.09)

AxoGen, Inc. to Report Second Quarter Financial Results on August 4, 2014
GlobeNewswire - Wed Jul 16, 3:52AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, will report results for the second quarter ended June 30, 2014 on Monday, August 4, 2014 after the close of the markets.
AXGN: 3.07 (-0.09)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 140

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 203

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 71

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 95

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 126

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 78

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 116

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 172

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading

Top 5 Most Recently Viewed Articles

Bitcoin Faces Criticism While BlackRock Sees Financial Success

Updated Category News Views 167

Bitcoin Under Scrutiny In recent discussions, Peter Schiff has taken to social media to share his critical views on Bitcoin, branding it as a "fake asset." His assertion comes after Bitcoin's price retracement from its historic highs, indicating a significant downturn. Currently, Bitcoin is trading at around $81,000 after once peaking at $110,000. Schiff argues that the...

Continue Reading
Valneva Secures $32.8 Million Contract for IXIARO Vaccine Supply

Updated Category News Views 213

Valneva Expands IXIARO Vaccine Supply with New Contract Valneva SE, a leading specialized vaccine company, has officially announced a significant step forward in its partnership with the U.S. Department of Defense (DoD) by signing a new contract valued at a minimum of $32.8 million for the IXIARO vaccine. This substantial agreement marks another chapter in Valneva's...

Continue Reading
EFGH and Minerva Forge Strategic Partnership for Data Centres

Updated Category News Views 118

EFGH and Minerva Unite to Enhance Ghana's Digital Landscape In a landmark agreement, Embed Financial Group Holdings (EFGH) has joined forces with Minerva Data Limited, a prominent player in digital infrastructure, to create advanced data centres and strengthen the technology ecosystem in Ghana. This collaboration marks a significant step in addressing the growing demand...

Continue Reading
Landsea Homes Achieves Remarkable Growth in Q3 Results

Updated Category News Views 50

Strong Financial Performance in Q3 Landsea Homes Corporation (NASDAQ: LSEA) reported impressive financial results for the third quarter, demonstrating robust performance in the residential homebuilding sector. For the quarter, Landsea Homes achieved a net income of $11.1 million, translating to $0.30 per share. This marks a 29% increase in net income compared to the...

Continue Reading
Urban Logistics REIT: Key Disclosure Insights for Investors

Updated Category News Views 219

Understanding the Disclosure from Urban Logistics REIT In the realm of public trading, disclosures play a pivotal role in keeping investors informed about changes in significant stakes within companies. Recently, Urban Logistics REIT Plc, underlining its commitment to transparency, provided valuable insights through its disclosure concerning investor positions, managed by...

Continue Reading